In HF patients, intravenous iron reduces both CV death and HF-related events

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-01-17 04:30 GMT | Update On 2024-01-17 07:22 GMT

A recent study published in the JACC: Heart Failure analyzed the guidelines that advocate the consideration of intravenous iron to reduce heart failure symptoms which showed positive impact on cardiovascular outcomes. This study was conducted by utilizing systematic review of randomized controlled trials from January 1, 2000, to August 26, 2023 and focused on patients with iron deficiency and heart failure.

This analysis encompassed 14 trials and 6,624 heart failure patients which revealed compelling results. Out of these, 3,407 were treated with intravenous iron while 3,217 received placebo. This comprehensive data unveiled a significant reduction in the risk of combined cardiovascular death and heart failure admission (OR: 0.838 [95% CI: 0.751-0.936]; P = 0.0015), cardiovascular death (OR: 0.867 [95% CI: 0.755-0.955]; P = 0.0427), first heart failure admission (OR: 0.855 [95% CI: 0.744-0.983]; P = 0.0281) and total heart failure admissions (rate ratio: 0.739 [95% CI: 0.661-0.827]; P < 0.0001).

This significance is further underscored by identifying the notable heterogeneity among trial results by concerning first and total heart failure admissions. Metaregression analysis highlighted variations in the baseline transferrin saturation (TSAT) levels which exhibited a more pronounced effect size on heart failure-related events by providing a crucial input into the nuanced relationship between iron status and treatment efficacy.

The observed reduction in cardiovascular death and heart failure-related events suggests a potential shift in the approach to heart failure treatment. Also, the study hints the relevance of baseline TSAT by indicating that patients with lower levels who might particularly benefit from this intervention. This study affirms its strong efficacy and also adds a layer by highlighting the influence of baseline TSAT by paving way for more personalized and effective interventions for heart failure management.

Source:

Martens, P., Augusto, S. N., Jr., Mullens, W., & Tang, W. H. W. (2023). Meta-Analysis and Metaregression of the Treatment Effect of Intravenous Iron in Iron-Deficient Heart Failure. In JACC: Heart Failure. Elsevier BV. https://doi.org/10.1016/j.jchf.2023.11.006

Article Source : JACC: Heart Failure

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Jacinthlyn Sylvia

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

In HF patients, intravenous iron reduces both CV death and HF-related events

Similar News

Women who have been stalked may have higher risk of heart disease, stroke, reports study

Heart Failure in Women: Updates from the National Consensus on Bisoprolol

No Clear Winner: Three Dual-Drug Hypertension Therapies Work Equally Well in Indian Adults, TOPSPIN Trial Finds

5 Lifestyle Habits May Cut Heart Disease Risk by 86 Percent in Women with Gestational Diabetes: Study Finds

Severe Gum Disease Strongly Linked to Chronic Illnesses, Large U.S. Study Finds

Fetal Embolization Exhibits Early Success in High-Risk Vein of Galen Malformation: JAMA

Gland Pharma secures USFDA okay for Norepinephrine Bitartrate in 5% Dextrose Injection Bags

Gland Pharma bags USFDA nod for Cangrelor for Injection